|
Press Releases |
|
 |
|
Tuesday, October 3, 2017 |
|
雅各臣完成發行本金總額為5億港元的可換股票據予Dragons 615 Limited及HH InRe JP, Ltd. |
從事非專利藥及品牌藥品研發、生產、市場推廣及銷售的領先企業─雅各臣科研製藥有限公司(「雅各臣」或「集團」;股份代號:2633)欣然宣佈已完成發行本金總額為5億港元的可換股票據予兩名認購人 more info >> |
|
Jacobson Pharma Issues HK$500M Convertible Notes to Dragons 615 Ltd and HH InRe JP, Ltd. |
Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Group"; Stock Code: 2633), a leading company engaged in the research, development, production, marketing and sale of generic drugs and proprietary medicines more info >> |
|
Wednesday, September 6, 2017 |
|
雅各臣发行5亿港元可换股票据予Dragons 615 Limited及HH InRe JP, Ltd. |
从事非专利药及品牌药品研发、生产、市场推广及销售的领先企业─雅各臣科研制药有限公司(「雅各臣」或「集团」;股份代号:2633)建议按一般授权发行二零二零年到期、本金总额5亿港元的可换股票据予两名认购人,分别为Dragons 615 Limited (「Dragons」,DCP China Credit Fund I, LP (「DCP Fund」)之全资拥有的有限公司)及HH InRe JP, Ltd. (「HH JP」,一间由Hillhouse InRe Fund, LP间接全资拥有的有限公司)。 more info >> |
|
雅各臣發行5億港元可換股票據予Dragons 615 Limited及HH InRe JP, Ltd. |
從事非專利藥及品牌藥品研發、生產、市場推廣及銷售的領先企業─雅各臣科研製藥有限公司(「雅各臣」或「集團」;股份代號:2633)建議按一般授權發行二零二零年到期、本金總額5億港元的可換股票據予兩名認購人,分別為Dragons 615 Limited (「Dragons」,DCP China Credit Fund I, L.P. (「DCP Fund」)之全資擁有的有限公司)及HH InRe JP, Ltd. (「HH JP」,一間由Hillhouse InRe Fund, L.P.間接全資擁有的有限公司)。 more info >> |
|
Jacobson Pharma Issues HK$500M of Convertible Notes to Dragons 615 and HH InRe JP, Ltd. |
Jacobson Pharma Corporation Limited , a leading company engaged in the research, development, production, marketing and sale of generic drugs and proprietary medicines, has proposed to issue Convertible Notes under general mandate, in an aggregate principal amount of HK$500 million due in 2020, to two subscribers namely Dragons 615 Limited and HH InRe JP, Ltd. more info >> |
|
Sunday, June 25, 2017 |
|
雅各臣公布二零一七年全年业绩 |
从事非专利药及品牌药品研发、生产、市场推广及销售的领先企业─雅各臣科研制药有限公司(「雅各臣」或「公司」;股份代号:2633)今天公布公司及附属公司(统称「集团」)截至二零一七年三月三十一日止年度(「二零一七财年」)的全年业绩,亦是公司在去年九月于香港上市后的首份全年业绩。 more info >> |
|
雅各臣公佈二零一七年全年業績 |
從事非專利藥及品牌藥品研發、生產、市場推廣及銷售的領先企業─雅各臣科研製藥有限公司(「雅各臣」或「公司」;股份代號:2633)今天公佈公司及附屬公司(統稱「集團」)截至二零一七年三月三十一日止年度(「二零一七財年」)的全年業績,亦是公司在去年九月於香港上市後的首份全年業績。 more info >> |
|
Jacobson Pharma Announces 2017 Annual Results |
Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Group"; Stock Code: 2633), a leading company engaged in the research, development, production, marketing and sale of generic drugs and proprietary medicines, has today announced its annual results of the Company and its subsidiaries (collectively the "Group") for the year ended 31 March 2017 ( "FY 2017" ). more info >> |
|
Wednesday, April 26, 2017 |
|
香港李众胜堂保济丸与「水滴无界」签订合作协议 |
李众胜堂(集团)有限公司(「李众胜堂」或「公司」)今天出席「水滴无界」于北京的上线启动仪式,并由代表与「水滴无界」签订合作协议,正式标志着双方展开于中国大陆市场携手合作的新里程。 more info >> |
|
香港李眾勝堂保濟丸與「水滴無界」簽訂合作協議 |
李眾勝堂(集團)有限公司(「李眾勝堂」或「公司」)今天出席「水滴無界」於北京的上線啟動儀式,並由代表與「水滴無界」簽訂合作協議,正式標誌著雙方展開於中國大陸市場攜手合作的新里程。 more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
How Do AI Workflow Automations Work?
Aug 16, 2025 00:00 HKT/SGT
|
|
|
Everest Medicines' New Drug Application for Etrasimod Accepted in Taiwan, Marking Another Milestone in Asia Market Access
Aug 15, 2025 23:18 HKT/SGT
|
|
|
Yuexiu REIT Maintains Overall Operational Stability, Achieves Revenue of Over RMB966 Million
Aug 15, 2025 23:17 HKT/SGT
|
|
|
The 35th Food Expo opens today
Aug 15, 2025 23:16 HKT/SGT
|
|
|
Shoucheng Joins World Humanoid Robot Games - 88 Spectators Invited
Aug 15, 2025 23:06 HKT/SGT
|
|
|
Etrasimod Receives Strong Recommendation in the ACG Clinical Guideline Update: Ulcerative Colitis in Adults for Induction and Maintenance Phase of Moderately to Severely Active UC
Aug 15, 2025 20:15 HKT/SGT
|
|
|
艾曲莫德入選《2025 ACG臨床指南:成人潰瘍性結腸炎》,獲強烈推薦用於中重度潰瘍性結腸炎的誘導緩解及維持緩解治療
Aug 15, 2025 20:07 HKT/SGT
|
|
|
艾曲莫德入选《2025 ACG临床指南:成人溃疡性结肠炎》,获强烈推荐用于中重度溃疡性结肠炎的诱导缓解及维持缓解治疗
Aug 15, 2025 19:56 HKT/SGT
|
|
|
OrbusNeich Records Growth in 2025 Interim Results, Revenue and Net Profit Reach US$83.6 Million and US$19.8 Million Respectively
Aug 15, 2025 19:11 HKT/SGT
|
|
|
業聚醫療2025年中期業績收入及純利雙雙增長 分別達8,360萬美元及1,980萬美元
Aug 15, 2025 18:53 HKT/SGT
|
|
|
业聚医疗2025年中期业绩收入及纯利双双增长 分别达8,360万美元及1,980万美元
Aug 15, 2025 18:10 HKT/SGT
|
|
|
RAK ICC Strengthens Foundations Regime with 2025 Legislative Enhancements
Aug 15, 2025 18:00 HKT/SGT
|
|
|
廣發証券榮膺國家數據管理能力成熟度(DCMM)最高等級認証
Aug 15, 2025 17:28 HKT/SGT
|
|
|
米国株式アクティブ残高10年連続世界No.1ティー・ロウ・プライス[1] 日本法人が既存追加型株式投資信託に「毎月決算・予想分配金提示型」ファンドを新規設定
Aug 15, 2025 17:15: JST
|
|
|
广发证券荣膺国家数据管理能力成熟度(DCMM)最高等级认证
Aug 15, 2025 17:12 HKT/SGT
|
|
|
|
More News >> |
|
|
|
|
|